Quick Facts

Diabetrol is a treatment option prescribed for the management of Type 2 Diabetes Mellitus in adult patients. This medication is typically utilized when modifications to diet and exercise alone have not achieved desired outcomes for blood glucose levels. Its principal use is to assist in maintaining glucose concentrations within a target range.

The central benefit of appropriate treatment is to improve overall glycemic control. By supporting the reduction of high blood sugar, Diabetrol may contribute to mitigating the potential for chronic, long-term health issues associated with this condition, such as nerve, kidney, and vision concerns. This medication is generally used as part of a comprehensive management strategy. Patients should adhere to the prescribed regimen to realize the potential for symptom relief and improved quality of life.

Who Can and Cannot Use Diabetrol?

Diabetrol is officially indicated for adults (18 years and above) with Type 2 Diabetes Mellitus. Its use is governed by strict population eligibility rules outlined in regulatory labeling.

Contraindications (Must Not Use)

The medicine is contraindicated for patients with Type 1 Diabetes Mellitus and individuals with known hypersensitivity to Glibenclamide, Metformin, or related components. It must not be used in the presence of acute metabolic conditions like Diabetic Ketoacidosis or Lactic Acidosis. Use is also prohibited in cases of severe renal failure (GFR less than 30 mL/min), severe hepatic insufficiency, and conditions causing tissue hypoxia (e.g., cardiac failure).

Special Population Restrictions

Diabetrol must not be taken during pregnancy or lactation. It is not recommended for use in children and adolescents under 18 years due to a lack of established safety and efficacy data. Older adults require careful dose adjustment and frequent renal monitoring. The medication must be temporarily discontinued before major surgery or radiological studies using iodinated contrast media.

Interactions with other medicines and products

Diabetrol, a fixed-dose combination of Glibenclamide and Metformin Hydrochloride, has officially documented interaction patterns structured around pharmacokinetic clearance and pharmacodynamic glucose modification.

Formal Interaction Restrictions

Exposure and Effect Modification

Certain medicines officially alter the components' activity or concentration. Renal Transporter Inhibitors, such as Cimetidine and Ranolazine, may increase the accumulation of Metformin, which elevates the risk of lactic acidosis. Other antidiabetic agents, beta-blockers, and MAOIs may cause pharmacodynamic potentiation, increasing the risk of hypoglycemia. Conversely, substances like Corticosteroids and Thiazide Diuretics may officially diminish the glucose-lowering action.

Timing and Population Notes

A timing rule requires administering Diabetrol at least 4 hours prior to Colesevelam to ensure Glibenclamide absorption. The risk of Metformin-related interactions is officially noted to be heightened in hepatic impairment and in populations with impaired renal function.

Diabetrol functions primarily by acting as a highly selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. This enzymatic interaction occurs in various tissues, including the endothelium and the pancreatic islet cells. By inhibiting DPP-4, Diabetrol significantly delays the cleavage and subsequent inactivation of the naturally occurring incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). The resulting elevation in the circulating plasma concentrations of active incretins leads to enhanced signaling through the GLP-1 and GIP receptors. This downstream cascade selectively stimulates insulin secretion from pancreatic beta-cells, specifically in a glucose-dependent manner, meaning the effect is pronounced when glucose levels are high. Simultaneously, the enhanced signaling reduces the secretion of glucagon from pancreatic alpha-cells. This dual physiological modulation of insulin and glucagon activity regulates glucose homeostasis by ultimately slowing gastric emptying and decreasing endogenous hepatic glucose production.

Administration Guidelines for Diabetrol (Glibenclamide/Metformin)

These guidelines detail the proper use of Diabetrol (a combination of glibenclamide and metformin).

Administration Scope

Special Procedural Conditions

Research evidence / Overview of studies for Diabetrol

Evidence for Managing Type 2 Diabetes Mellitus

The foundation of the evidence for Diabetrol (Glibenclamide and Metformin fixed-dose combination) comes primarily from Randomized Controlled Trials (RCTs). These are studies where patients are randomly assigned to receive either the combination medicine, a single-agent treatment, or sometimes a placebo, to explore specific measured outcomes related to blood sugar. Research has examined the use of this combination in two main contexts: as a starting treatment for newly diagnosed adults and in patients previously receiving single-agent therapy whose blood sugar levels remained a focus of study.

Evaluating Initial Therapy vs. Combination Therapy

When evaluated in the context of initial treatment, research explored the combination in adults with Type 2 Diabetes who are not yet taking other medication. These short-to-intermediate-term studies monitored outcomes such as Glycated Hemoglobin ( HbA1c), a biomarker for average blood sugar levels, as well as Fasting Plasma Glucose (FPG) measurements. Studies monitored these blood sugar biomarkers, and patterns of measured outcomes were reported across the combination group and the comparator groups over the study period.

Follow-up durations for these initial comparison trials were observed over defined time intervals, typically several months or up to a year. This means the evidence describes patterns of short-term observation, but long-term effects are not fully established for the combination used in this context.

Evidence in Patients Uncontrolled on Monotherapy

Diabetrol was studied for use in adults with Type 2 Diabetes whose blood sugar was still considered high despite the use of a single antidiabetic medicine. These RCTs were designed to monitor measured blood sugar levels in the observed populations following the initiation of the combination. The research examined changes in HbA1c and FPG, with studies reporting patterns of measured biomarkers in the combination group relative to the single-drug therapy group.

Some trials reported patterns of measured outcomes in certain patient groups, such as those with lower initial HbA1c values, when compared to other groups. This suggests that results apply only to the populations studied, and evidence quality varies across studies when analyzing specific patient subgroups.

Long-Term Studies and Durability of Response

Clinical trials specifically designed to study the fixed-dose combination are typically of intermediate-term duration, limiting direct evidence on sustained effects over many years. Therefore, the understanding of long-term outcomes for the combination is often extrapolated from research scenarios where the individual component drugs—Metformin and Glibenclamide—were observed in studies over extended periods.

Long-term follow-up studies extending to multiple years was observed in research exploring the component drug classes. These studies monitored data on major macrovascular events and all-cause mortality documented in the context of diabetes. These long-term observational settings provide data on long-term outcomes for the component drugs, but this evidence does not represent multi-year, fixed-dose combination RCT data.

Evidence in Specific Patient Populations

Research has explored the use of Diabetrol's components in certain patient groups to understand how measured outcomes might differ. One focus was on patients with high levels of HbA1c at the start of the study; studies reported patterns of measured outcomes in these specific subgroups.

Additionally, the combination was studied for use in pediatric or adolescent populations with Type 2 Diabetes. The research explored blood sugar biomarkers in these younger groups. However, when comparing the combination to monotherapy in this group, findings were mixed, and the evidence for a consistent difference between the combination and monotherapy in the overall pediatric population remains limited. Consequently, subgroup findings are uncertain, and data for certain groups remain insufficient.

What Remains Uncertain or Requires Further Research

While studies help show what has been observed so far, there are specific aspects of Diabetrol's use where certainty remains low or where comparative evidence is lacking.

• Trial Duration: The core research comparing the combination to single drugs typically uses follow-up durations that were limited to less than one year, meaning the full picture of long-term effects are not fully established.
• Complication Data: The evidence base for the combination’s influence on long-term clinical endpoints is mostly extrapolated from separate, long-term studies of the individual drug components, and comparative evidence is lacking for the specific fixed-dose tablet over many years.
• Population Gaps: As noted, findings were mixed for certain subgroups, and data are still emerging for certain patient groups not heavily represented in the initial large-scale RCTs.

Key Studies & References

1. Metformin and Glyburide (Oral Route) – MedlinePlus Drug Information

Common questions about Diabetrol (FAQ)

Q: Are there any major diet changes required while using Diabetrol?

A: Regulatory documents state that Diabetrol is intended for use along with a carefully followed diet and exercise program. Official guidance emphasizes that adhering to the meal plan provided by a healthcare professional is relevant for metabolic support.

The medicine is described in official guidelines as being taken with meals that contain sufficient carbohydrate content.

Q: What happens if I miss taking Diabetrol sometimes?

A: If one dose is missed, official administration instructions specify that a double dose should not be taken to compensate. Official guidance indicates patients may resume the regular dosing schedule with the next planned dose.

Q: Is Diabetrol safe for long-term use?

A: Regulatory documents do not define a specific maximum duration of use. However, the official warnings mention that long-term exposure to the medication requires attention.

The official label suggests that periodic monitoring of specific parameters, such as the documented risk of a reduction in serum Vitamin B12 levels, is relevant.

Q: Are there any vitamins or supplements that should not be taken with Diabetrol?

A: Official labeling indicates that the metformin component can potentially lower Vitamin B12 levels, and monitoring is recommended. Because many nonprescription products, including vitamins and supplements, can influence the drug's activity, official information indicates that discussing these products with a healthcare professional is relevant.

Q: Does Diabetrol interact with common over-the-counter pain relievers?

A: Regulatory documents detail interactions with specific drug classes and advise caution regarding all nonprescription medicines. Official product information emphasizes that nonprescription products, such as aspirin, should be discussed with a healthcare professional before use, as many medicines can affect blood sugar control.

Q: Does Diabetrol have a warning about driving or operating machinery?

A: Official warnings note the risk of hypoglycemia (low blood sugar), which can affect concentration and reaction time. Official documents mention consulting a healthcare professional is relevant if symptoms are experienced that could potentially impair the ability to concentrate and react, such as while driving.

Q: What are the reasons someone might need to stop taking Diabetrol?

A: The medicine may be temporarily or permanently discontinued due to specific medical reasons listed in the regulatory documents. This includes temporary discontinuation 48 hours before major surgery or certain radiological procedures, or permanent stopping due to conditions like severe renal impairment or metabolic acidosis.

Q: What does official guidance say about using Diabetrol during pregnancy or breastfeeding?

A: Official guidance states that Diabetrol is generally not recommended for use during pregnancy or lactation. Official guidance indicates that healthcare professional assessment and counseling on contraception or pregnancy planning may be relevant for premenopausal women.

Q: Does Diabetrol interact with alcohol?

A: Excessive consumption of alcohol (ethanol) is formally contraindicated with this medication. This restriction is due to alcohol potentiating the effect of metformin, which significantly increases the risk of lactic acidosis and severe low blood sugar (hypoglycemia).

Q: What happens if Diabetrol is taken with specific food types?

A: Regulatory studies show that taking the drug with meals helps reduce stomach side effects. Pharmacokinetic data indicates that food generally slows down and slightly reduces the absorption of the metformin component.

Official guidance emphasizes taking the medicine with meals, but detailed administration differences between high-fat versus low-fat meals are generally not specified in the labeling.

Q: Is Diabetrol considered a new type of medicine?

A: Official product information describes Diabetrol as a fixed-dose combination containing two distinct established medicines: Glibenclamide (a sulfonylurea) and Metformin (a biguanide). Both components belong to well-established pharmacological classes of oral antihyperglycemic drugs.

Q: How quickly does Diabetrol start working after taking it?

A: Regulatory documents indicate that the metformin component reaches its peak plasma concentration in approximately 2 to 4 hours after dosing. Steady state concentrations are generally reached within 24 to 48 hours with regular administration.

Q: Why do some people say they feel tired when they first start Diabetrol?

A: Regulatory documents list extreme tiredness and weakness as potential symptoms of a rare but serious side effect called Lactic Acidosis. Tiredness can also be associated with hypoglycemia (low blood sugar) or anemia (due to B12 deficiency) listed in the safety profile.

Q: Is it normal to feel a change in appetite while on Diabetrol?

A: Official documents list a loss of appetite (anorexia) as one of the most frequently occurring gastrointestinal disturbances reported with the medicine. This effect is often observed during the initial phase of treatment.

Q: Is Diabetrol available in different strengths?

A: According to official product labeling, the fixed-dose combination of Glibenclamide/Metformin is officially available in multiple strengths. These multiple strengths are used to allow for gradual dosage adjustment based on metabolic response.

Q: How long does the effect of one dose of Diabetrol typically last?

A: Pharmacokinetic data shows the elimination half-life of the metformin component is about 6.2 hours from plasma, and the glibenclamide component is shorter. This data influences the dosing frequency, which is typically once, twice, or three times daily as administered.

Q: Do the official documents mention any effects of Diabetrol on weight?

A: Clinical trial summaries in regulatory documents include data where researchers monitored and reported the mean changes from baseline in patient Body Weight over the study duration. This data is part of the established safety and efficacy research.

Q: Can Diabetrol cause problems if I have a history of pancreatitis?

A: Regulatory guidance related to the Metformin component's alcohol interaction advises caution. Official warnings note that patients with a history of pancreatitis may need to avoid consuming alcohol while on therapy due to the documented increase in associated risks.

Q: Are there any specific safety monitoring recommendations while taking Diabetrol?

A: Official warnings describe specific safety monitoring parameters that are relevant when taking the medicine. This includes the periodic measurement of hematological parameters (blood cell counts), Vitamin B12 levels, and frequent assessment of renal function for certain populations, such as older adults.

Q: Is it common to experience skin reactions when using Diabetrol?

A: Official documents note that various allergic skin reactions (such as rashes, itching, and redness) are adverse reactions reported for the Glibenclamide component. These reactions were observed in approximately 1.5% of treated patients in clinical studies.

Q: Do any official sources mention Diabetrol affecting fertility?

A: Official documents advise premenopausal females of the potential for an unintended pregnancy due to the drug's effect on ovulation in certain patients. Nonclinical studies have also been used to examine potential effects on fertility.

Q: Are headaches a common initial side effect of Diabetrol?

A: Clinical trial summaries in official regulatory documents list headache as one of the commonly reported adverse reactions associated with the use of the medicine.

Q: What is the chemical name of Diabetrol’s active ingredient?

A: The official description section of the product labeling provides the full chemical names. The two active ingredients are Glibenclamide (a sulfonylurea) and Metformin Hydrochloride (a biguanide).

Q: What are the least common but serious side effects reported for Diabetrol?

A: Official regulatory labels specify several Serious Adverse Reactions. These include the Very Rare occurrence of Lactic Acidosis and other rare effects such as severe hematological reactions and hepatic dysfunction (jaundice or hepatitis).

Q: Do studies show Diabetrol works better for certain types of people?

A: Clinical studies have examined certain subgroups of patients, such as those with different starting blood sugar levels. However, official research reports that findings were mixed for certain subgroups, and evidence for a consistent difference between groups remains limited.

Q: Can I use natural herbal remedies while taking Diabetrol?

A: Official guidance warns that many other medicines may affect blood sugar control or increase the risk of side effects. Official guidance emphasizes that discussing all nonprescription medicines and similar products, including herbal and natural remedies, with a healthcare professional is relevant before use.

Q: Why is Diabetrol sometimes mentioned with cholesterol medicines?

A: Regulatory documents include a specific timing rule for one type of cholesterol-lowering medicine, Colesevelam. Diabetrol must be administered at least 4 hours prior to this medicine to ensure proper absorption of the glibenclamide component.

Q: Does Diabetrol need to be kept refrigerated?

A: Official storage requirements instruct patients to store the tablets at Controlled Room Temperature (20 C to 25 C). The guidance specifies that the medicine should be protected from moisture and light, but refrigeration is not required.

The storage and disposal of Diabetrol (Glibenclamide and Metformin Hydrochloride) must follow the official regulatory requirements for maintaining product integrity.

Official Storage Requirements

Disposal Instructions

Expired or unused Diabetrol should be discarded via a local drug take-back program or by following official household disposal guidance. The regulatory standard instructs that the medicine must not be flushed down the toilet or poured into a drain.